NOVO Nordisk Pharmaceuticals
has engaged Kos Sclavos, former
Pharmacy Guild president, to
develop a patient program for
community pharmacies to address
Australia’s obesity epidemic.
“The community pharmacist
will have an important role to
play in addressing this epidemic,
as they not only have insight into
the weight-related comorbidities
being treated in a person living with
obesity, but can also respond to
direct questions from the public.”
With so many options on
the market, Sclavos said “the
pharmacist is the ideal person to
provide advice as to which options
are based on scientific evidence,
and which options may have little
or no proven effectiveness”.
Novo Nordisk has just received
approval to market Saxenda
(liraglutide (rys)) in Australia as a
first-in-class treatment for chronic
weight management.The above article was sent to subscribers in Pharmacy Daily's issue from 29 Jan 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 29 Jan 16
BREAST Cancer Network Australia (BCNA) has welcomed a PBAC recommendation to subsidise the breast cancer drug Enhertu (trastuzumab deruxtecan) for HER2-low metastatic breast cancer on the PBS.
PHARMACY Connect (PC2024) has revealed that Olympian Peter Bol will be sharing his journey from adversity to athletic greatness at the conference in Sep in Sydney.
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.